China National Biotec

China National Biotec Group (CNBG) is a leading Chinese biopharmaceutical company and a core subsidiary of the state-owned Sinopharm. As the largest developer and manufacturer of vaccines and blood products in China, CNBG provides over 80% of the vaccines used in the country's National Immunization Program. The company operates through six major regional institutes of biological products and has achieved global prominence for its development of WHO-prequalified vaccines, including two major inactivated COVID-19 vaccines. Beyond its vaccine portfolio, CNBG is a dominant player in the Chinese plasma-derived therapies market and is actively expanding into recombinant proteins and monoclonal antibodies. The organization plays a vital role in both China's public health infrastructure and international health initiatives through partnerships with global health organizations.